Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.

被引：6
|
作者：
Klempner, Samuel J.
Lee, Keun-Wook
Metges, Jean-Philippe
Catenacci, Daniel V. T.
Loupakis, Fotios
Ilson, David H.
Shah, Manish A.
Shitara, Kohei
Arozullah, Ahsan
Park, Jung Wook
Raizer, Jeffrey J.
Bang, Yung-Jue
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea
[3] Hop Morvan, Ctr Hosp Reg Univ Brest, Brest, France
[4] Univ Chicago, Gastrointestinal Oncol Program, Chicago, IL 60637 USA
[5] Univ Azienda Osped Univ Pisana, Pisa, Italy
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Weill Cornell Med Coll, New York, NY USA
[8] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[9] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[10] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16063
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
    Bang, Y-J
    Kang, Y-K
    Ng, M.
    Chung, H. C.
    Wainberg, Z. A.
    Gendreau, S.
    Chan, W. Y.
    Xu, N.
    Maslyar, D.
    Meng, R.
    Chau, I
    Ajani, J. A.
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 17 - 24
  • [22] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Ajani, J. A.
    Lordick, F.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Shah, M. A.
    van Cutsem, E.
    Xu, R-H.
    Aprile, G.
    Xu, J.
    Pazo Cid, R. A.
    Kang, Y-K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Matsangou, M.
    Arozullah, A.
    Park, J. W.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1525
  • [23] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Ajani, J. A.
    Lordick, F.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R-H.
    Aprile, G.
    Xu, J.
    Cid, R. A. Pazo
    Kang, Y-K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Matsangou, M.
    Arozullah, A.
    Park, J. W.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1322 - S1322
  • [24] JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Alsina, Maria
    Weinberg, Zev A.
    Chau, Ian
    Zhu, Jin
    Chan, Wai Y.
    Patel, Premal H.
    Meng, Raymond D.
    Ajanl, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)
    Shitara, Kohei
    Xu, Rui-Hua
    Moran, Diarmuid Martin
    Guerrero, Abraham
    Li, Ran
    Pavese, Janet
    Matsangou, Maria
    Bhattacharya, Pranob P.
    Ajani, Jaffer A.
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (vol 401, pg 1655, 2023)
    Shitara, K.
    Lordick, F.
    Bang, Y-J
    LANCET, 2023, 402 (10398): : 290 - 290
  • [27] Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
    Shitara, Kohei
    Lordick, Florian
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Shah, Manish A.
    Van Cutsem, Eric
    Xu, Rui-hua
    Aprile, Giuseppe
    Xu, Jianming
    Chao, Joseph
    Pazo-Cid, Roberto
    Kang, Yoon-Koo
    Yang, Jianning
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Park, Jung Wook
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA292 - LBA292
  • [28] Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER22, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Shitara, Kohei
    Van Cutsem, Eric
    Lordick, Florian
    Enzinger, Peter C.
    Ilson, David H.
    Shah, Manish A.
    Xu, Rui-Hua
    Lonardi, Sara
    Yamaguchi, Kensei
    Hung, Yi-Ping
    Kukielka-Budny, Bozena
    Bhattacharya, Pranob P.
    Matsangou, Maria
    Li, Ran
    Moran, Diarmuid Martin
    Ranganath, Radhika
    Pophale, Rupesh
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET plus ) adenocarcinoma of the stomach or gastroesophageal junction (GEC)
    Shah, Manish A.
    Bang, Yung-Jue
    Lordick, Florian
    Tabernero, Josep
    Chen, Meng
    Hack, Stephen Paul
    Phan, See-Chun
    Shames, David S.
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Lordick, F.
    Shah, M. A.
    Shitara, K.
    Ajani, J. A.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Van Cutsem, E.
    Plazas, J. Gallego
    Huang, J.
    Shen, L.
    Oh, S. C.
    Sunpaweravong, P.
    Soo, H. H. F.
    Turk, H. M.
    Park, J. W.
    Moran, D.
    Bhattacharya, P.
    Cao, Y. J.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1321 - S1321
12345